Log in

NASDAQ:BSTCBioSpecifics Technologies Stock Price, Forecast & News

$58.38
+1.99 (+3.53 %)
(As of 04/10/2020 06:44 AM ET)
Add
Compare
Today's Range
$54.54
Now: $58.38
$58.75
50-Day Range
$44.01
MA: $54.97
$64.87
52-Week Range
$42.00
Now: $58.38
$70.00
Volume53,600 shs
Average Volume64,655 shs
Market Capitalization$428.51 million
P/E Ratio17.58
Dividend YieldN/A
Beta1.01
BioSpecifics Technologies Corp., a biopharmaceutical company, engages in the development of an injectable collagenase clostridium histolyticum for various indications in the United States and internationally. The company offers injectable collagenase for the treatment of Dupuytren's contracture and Peyronie's disease under the XIAFLEX or Xiapex brands. It also provides injectable collagenase to treat frozen shoulder, cellulite, canine lipoma, lateral hip fat, plantar fibromatosis, and human lipoma, as well as uterine fibroids. In addition, the company engages in the development of other clinical indications for which collagenase injection has been tested, such as keloids, hypertrophic scars, scarred tendons, glaucoma, herniated intervertebral discs, and as an adjunct to vitrectomy. BioSpecifics Technologies Corp. has a development and license agreement with Endo Global Ventures. The company was founded in 1957 and is headquartered in Lynbrook, New York.
Read More
BioSpecifics Technologies logo

Beat the Market (BTM) Rank

Analyst Opinion: 3.5Community Rank: 2.6Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.42 out of 5 stars


Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryBiotechnology
SectorMedical
Current SymbolNASDAQ:BSTC
CUSIP09093110
Phone516-593-7000

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$38.19 million
Cash Flow$3.50 per share
Book Value$16.96 per share

Profitability

Net Income$24.47 million

Miscellaneous

Employees6
Market Cap$428.51 million
Next Earnings Date5/8/2020 (Estimated)
OptionableNot Optionable

Receive BSTC News and Ratings via Email

Sign-up to receive the latest news and ratings for BSTC and its competitors with MarketBeat's FREE daily newsletter.


BioSpecifics Technologies (NASDAQ:BSTC) Frequently Asked Questions

How has BioSpecifics Technologies' stock been impacted by COVID-19 (Coronavirus)?

BioSpecifics Technologies' stock was trading at $55.93 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, BSTC shares have increased by 4.4% and is now trading at $58.38. View which stocks have been most impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of BioSpecifics Technologies?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for BioSpecifics Technologies in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for BioSpecifics Technologies.

When is BioSpecifics Technologies' next earnings date?

BioSpecifics Technologies is scheduled to release its next quarterly earnings announcement on Friday, May 8th 2020. View our earnings forecast for BioSpecifics Technologies.

How were BioSpecifics Technologies' earnings last quarter?

BioSpecifics Technologies Corp. (NASDAQ:BSTC) announced its earnings results on Monday, March, 16th. The biopharmaceutical company reported $1.00 EPS for the quarter, topping analysts' consensus estimates of $0.94 by $0.06. The biopharmaceutical company earned $11.76 million during the quarter, compared to analysts' expectations of $10.41 million. BioSpecifics Technologies had a net margin of 64.08% and a return on equity of 21.56%. View BioSpecifics Technologies' earnings history.

What price target have analysts set for BSTC?

1 brokers have issued 12-month price targets for BioSpecifics Technologies' stock. Their forecasts range from $90.00 to $90.00. On average, they expect BioSpecifics Technologies' stock price to reach $90.00 in the next twelve months. This suggests a possible upside of 54.2% from the stock's current price. View analysts' price targets for BioSpecifics Technologies.

Has BioSpecifics Technologies been receiving favorable news coverage?

Media coverage about BSTC stock has trended very negative on Friday, InfoTrie Sentiment Analysis reports. InfoTrie ranks the sentiment of press coverage by analyzing more than six thousand blog and news sources in real-time. The firm ranks coverage of companies on a scale of negative five to five, with scores nearest to five being the most favorable. BioSpecifics Technologies earned a coverage optimism score of -3.3 on InfoTrie's scale. They also assigned news headlines about the biopharmaceutical company a news buzz of 0.0 out of 10, meaning that recent press coverage is extremely unlikely to have an impact on the company's share price in the immediate future. View the latest news aboutBioSpecifics Technologies.

Who are some of BioSpecifics Technologies' key competitors?

What other stocks do shareholders of BioSpecifics Technologies own?

Based on aggregate information from My MarketBeat watchlists, some companies that other BioSpecifics Technologies investors own include AbbVie (ABBV), Biogen (BIIB), Corbus Pharmaceuticals (CRBP), Inovio Pharmaceuticals (INO), Alibaba Group (BABA), Clovis Oncology (CLVS), Heron Therapeutics (HRTX), Jazz Pharmaceuticals (JAZZ), Momo (MOMO) and NVIDIA (NVDA).

Who are BioSpecifics Technologies' key executives?

BioSpecifics Technologies' management team includes the following people:
  • Dr. Ronald Law J.D., Ph.D., Interim Principal Exec. Officer (Age 66)
  • Mr. Patrick M. Caldwell, Interim Principal Financial Officer (Age 57)
  • Carl A. Valenstein, Corp. Sec.

What is BioSpecifics Technologies' stock symbol?

BioSpecifics Technologies trades on the NASDAQ under the ticker symbol "BSTC."

How do I buy shares of BioSpecifics Technologies?

Shares of BSTC can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is BioSpecifics Technologies' stock price today?

One share of BSTC stock can currently be purchased for approximately $58.38.

How big of a company is BioSpecifics Technologies?

BioSpecifics Technologies has a market capitalization of $428.51 million and generates $38.19 million in revenue each year. The biopharmaceutical company earns $24.47 million in net income (profit) each year or $3.33 on an earnings per share basis. BioSpecifics Technologies employs 6 workers across the globe. View additional information about BioSpecifics Technologies.

What is BioSpecifics Technologies' official website?

The official website for BioSpecifics Technologies is http://www.biospecifics.com/.

How can I contact BioSpecifics Technologies?

BioSpecifics Technologies' mailing address is 35 Wilbur Street, Lynbrook NY, 11563. The biopharmaceutical company can be reached via phone at 516-593-7000 or via email at [email protected]

This page was last updated on 4/10/2020 by MarketBeat.com Staff

Featured Article: Hedge Funds Explained

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel